What is the equity of Savara this year?
Savara has equity of 140.37 M USD this year.
Savara Equity 2024
Savara Equity
140.37 M USD
Ticker
SVRA
ISIN
US8051111016
WKN
A2DQ2B
In 2024, Savara's equity was 140.37 M USD, a 30.22% increase from the 107.8 M USD equity in the previous year.
Savara Aktienanalyse
What does Savara do?
Savara Inc is a US biotechnology company specializing in the development and commercialization of therapies for rare respiratory diseases. The company was founded in 2007 and is headquartered in Austin, Texas. Savara initially focused on treating cystic fibrosis, a genetic disease that can cause severe lung problems. The company developed an innovative therapy based on the use of liposomes, tiny bubbles that can deliver medication directly to the lungs. This method was considered promising and received orphan drug status from the FDA, meaning it is intended for the treatment of rare diseases. However, due to high costs associated with developing and approving a new medication for cystic fibrosis, Savara decided to redefine its goals and focus on other rare respiratory diseases. The company's business model is based on identifying promising therapy approaches for these diseases and developing them into approvable medications. Savara collaborates closely with leading experts and scientists in the field of respiratory diseases. Its main therapy areas include cystic fibrosis, pulmonary fibrosis, and rare lung diseases. Savara has a special focus on developing liposome-based therapies, which have the potential to target the affected areas in the lungs and enhance the effects of other medications. Currently, the company offers three products: - AeroVanc: A liposome-based inhaled antibiotic used to treat cystic fibrosis-induced chronic lung infections. AeroVanc is the first FDA-approved medication in Savara's history. - Molgradex: A recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for the treatment of autoimmune pulmonary alveolitis (also known as extrinsic allergic alveolitis). - AVAIL: A liposome-based inhaled antibiotic currently in Phase II of clinical development, being developed to treat non-tuberculous mycobacterial (NTM) lung infections. Savara has also formed partnerships with other companies and organizations to advance its research and development. Partners include the Cystic Fibrosis Foundation, the National Institutes of Health (NIH), and the European Respiratory Society. In summary, Savara Inc is a biotechnology company focused on developing therapies for rare respiratory diseases. The company has developed a promising technology platform and collaborates closely with leading experts and scientists in the field. Savara has a range of products on the market, including the first FDA-approved medication in the company's history. Savara ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Savara's Equity
Savara's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Savara's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Savara's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Savara's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Savara’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Savara stock
What was the equity of Savara compared to the previous year?
The equity of Savara has increased/decreased by 30.22% increased compared to the previous year.
What impact does a high equity have on investors of Savara?
A high equity is advantageous for investors of Savara as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Savara?
A low equity can be a risk for investors of Savara, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Savara affect the company?
An increase in equity of Savara can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Savara affect the company?
A reduction in equity of Savara can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Savara?
Some factors that can affect the equity of Savara include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Savara so important for investors?
The equity of Savara is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Savara take to change the equity?
To change equity, Savara can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Savara pay?
Over the past 12 months, Savara paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Savara is expected to pay a dividend of 0 USD.
What is the dividend yield of Savara?
The current dividend yield of Savara is .
When does Savara pay dividends?
Savara pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Savara?
Savara paid dividends every year for the past 0 years.
What is the dividend of Savara?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Savara located?
Savara is assigned to the 'Health' sector.
Wann musste ich die Aktien von Savara kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Savara from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.
When did Savara pay the last dividend?
The last dividend was paid out on 10/1/2024.
What was the dividend of Savara in the year 2023?
In the year 2023, Savara distributed 0 USD as dividends.
In which currency does Savara pay out the dividend?
The dividends of Savara are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Savara
Our stock analysis for Savara Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Savara Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
